Member Info for ciaskin

Just surmising but I wouldn't at all be surprised if it were Genentech. Top top antibody player...Project Blueprint partner... Ira Mellman views on avidity retweeted by SCLP... past RG references to good fit for SCLP with Roche (owner of Genentech) etc...etc... AIMHO. Good luck all. C.

...for Seneca Growth Fund (formerly Hygea) who hold over 13 million SCLP shares:

Scancell is an AIM listed biotechnology company that is developing a pipeline of therapeutic vaccines to target various types of cancer, with the first target being melanoma. The Immunobody platform technology, in effect, educates the immune system how to respond - this means that the technology can also be licensed to pharmaceutical companies to assist the development of their own therapeutic vaccines, which is an area of emerging importance for which a number of big pharmas do not have in-house technology.
In addition, in 2012 a second platform technology, Moditope, was announced and is based on exploiting the normal immune response to stressed cells, and is complementary to the Immunobody platform.

Progress made by the company in 2018 includes:

· The announcement of a Clinical Development Partnership with Cancer Research UK (CRUK) to develop SCIB2, for the treatment of patients with solid tumours, including non-small cell lung cancer. CRUK will fund and sponsor a UK-based Phase I/II clinical trial of SCIB2 in combination with a checkpoint inhibitor;

· The announcement of a collaboration with BioNTech for the Moditope product being developed for the treatment of lung, triple-negative breast cancer, ovarian and endometrial cancers. BioNTech is one of Europe's new immuno-oncology power-houses;

· The appointment of a new CEO in January 2018. He was VP Business Development at Arana when it acquired Scancell's monoclonal antibody business in 2006; and

· The initiation of preparations for a) a SCIB1- checkpoint inhibitor Phase II US combination study in late stage melanoma (the study is expected to start in H2 2019), and b) a First-in-Human study with Modi-1 in patients with triple negative breast cancer, ovarian cancer and sarcoma.

ALSO:

"In the Board's opinion, the intrinsic values of Scancell remain and we are firmly of the view that the potential upside in these assets merits their continued presence in the portfolio"

In short, they're happy to hold - and so am I.

GLA

C

The brakes are off...

1.98 paid now. Come on RENE!!!

The day is young. £1.965 just paid and £2.00 will surely fall...

Is almost 50% more than RENE's entire market cap!!! Game changer.

£2.97 break even for me, so it's good now to be less than 50% down!! It definitely feels like something is stirring though, and signposting end of April as another possible good news/inflection point should help to keep the rise sustained. Good luck all - especially LTHs!

Definitely some thing afoot...

Also, when releasing the Proactive RNS, why did they not update the 'About Scancell' footer to include Modi-2? It's hardly rocket science. It's just about getting the basics right.

Totally agree , Berm. And if it's IR, then shouldn't FTI be doing some of this rather than Sally?

As FTI are Scancell's investor relations agency (Simon Conway & Mo Noonan, details at the foot of most RNSs) perhaps they might do a better job in communicating these things to investors?

Morning Ivy & Douve...

I've been back to check the original context of the 'near to short term' comment. This was at the Proactive Interview was back in February when CH said:

“For me it all starts with great science, and from great science comes great products, and great products lead to great data, and great data leads to great deals. So I see Scancell now really moving through that trajectory towards the latter half of that equation and I think this is a time where the company is going to be able to be in a position to monetize some of its assets over the near to short term.”

Having attended the AGM and heard CH's answer, I am now happy with that. This is why:

I see it as a bit like a relay race where the the four legs are 1) Science>2) Products>3) Data>4) Deals. Unlike a relay, these are not equidistant legs but the longest part of the race has already been run: we HAVE great science and we HAVE great products. It has taken a significant amount of time to get this far but we are clearly now into the third stage of four, as confirmed at the AGM. Or, to quote CH, we ARE now in 'the latter half of that equation' and once the trials start, it won't take long to get the results. Remember too that meaningful, validating data could actually come at any time from anywhere (e.g. BioNtech, CRUK etc),

So yes, we are more than half way round the 'track' and monetization is beginning to come into sight. Relative to the development time so far, I guess this is 'short to near term'.

At the risk of milking the analogy, we may not yet be in the home straight, but I think we're certainly on or around around the final bend!

AIMHO.

GLA.

C

Hi Da. Yes, Richard was on the panel too. He was not asked any direct questions, but worked the room well afterwards.

Hi Ivy. No we didn't get the chance to speak (I asked the question about 'short to near term') but hopefully we can meet next year - if no EGM before, that is!! Thanks for all the notes too. C

JC & CH answered most. Given a pretty rough ride, TBH, but handled pretty well. Remuneration puts them only in the third quartile of equivalent biotech roles (Source: OBN network) Good data leads to good deals (yes, I know...) so patience is still needed. The delay to the SCIB 1 combo was unexpected, but solvable. The Trigrid 2.0 device works, it's just the data support that was lacking. MODI 1 has been later due to the complexity of manufacturing, but that is now sorted. No cash deals yet, but CRUK taking on SCIB 2 is worth c£20 million that SCLP will not have to fund so is extremely valuable. Cash burn is c £350k per month. That's just about everything I can decipher from my notes. Please feel free to add or correct - those that were there! Overall, a very frank discussion with difficult questions tackled. Science stronger than ever and only one element of the pipeline needs to come good to transform things. Glad I went and happy to hold. GLA. C.

Manufacturing of MODI1 has been difficult, mainly because hydrophobic peptides are required - not the easiest, apparently. However, between them, Lindy and the Polypeptide Group (PPG) have got it sorted and I got the impression that manufacturing may already have begun. MODI 1 can be modified in countless ways and MODI 2, which works by homocitrullination , is the first of these. Patent for MODI 2 has been submitted a couple of weeks ago. Not sure if this was in US or Europe. Can any other attendee clarify?

After CH, next up was Sally Adam. Not seen her present before, but very impressive. SCIB 1 Combo trial will involve 25 patients (6 for toxicity, dosing escalation etc) plus 19. Small number, yes, but statistically relevant. Keytruda control rate is 30%. Combo expected to take that to 55%. UK element to trial so that Lindy can more readily look at immune responses. Huge amount of work done for the FDA submission - SCIB 1 clinical study report alone ran to 2,688 pages!

Long day, but notes as follows: 35 - 40 in attendance, mainly PIs, I would guess. CH opened proceedings with usual background to IO market size/ potential etc. Ran through the SCLP pipeline & timelines. SCIB 1 Combo held up by FDA questions, but these principally relate to the device. Modi 1 will be in clinic in 2019 and more announcements about the BioNtech research partnership expected as we go into 2019.

Or maybe not...Legal Challenge has just FAILED and High Court has approved UK FRACKING!!

Strap yourselves in for the ride!

Are people still getting notifications from FTI when new RNSs are issued - such as this morning's? I've noticed that they have sent me nothing about the last 2 or 3 which isn't exactly great PR. News is rare enough on SCLP; I would have thought that when there us an RNS, they would let as many people know as possible...